Personalized peptide therapy may offer alternatives to traditional pharmaceuticals for issues such as chronic inflammation and post-surgical recovery when used with proper oversight
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Patel T, Zhou J, Piepmeier JM, Saltzman WM (2012) Polymeric nanoparticles for drug delivery to the central nervous system
Growth Factor Activation BPC-157 has been shown to upregulate growth factor receptors, including those involved in tendon-to-bone healing and soft tissue repair
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications approved by the FDA for managing type 2 diabetes and, in some formulations, for chronic weight management
